Abstracts Archive - Page 24 of 2425 - ACR Meeting Abstracts

Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…
Abstract Number: 0099 • ACR Convergence 2024
Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome
Kaitlyn Sabb¹, Ajay Tambralli¹, Megan Radyk¹, Emily Becker¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh², Jacqueline Madison¹, Yu Zuo¹, Costas Lyssiotis¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…
Abstract Number: 0108 • ACR Convergence 2024
Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Fernanda Oliveira de Andrade Lopes¹, Andreia Coimbra Sousa², Massimo Radin³, Gustavo Balbi⁴, Irene Cecchi³, Savino Sciascia⁵, Flavio Victor Signorelli⁶ and Danieli Andrade², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²University of São Paulo, São Paulo, SP, Brazil, ³University of Turin, Turin, Italy, ⁴Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, ⁵University of Turin, Torino, Turin, Italy, ⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
Abstract Number: 0287 • ACR Convergence 2024
Joint Involvement in Cystic Fibrosis: Description of Clinical Phenotypes
Omar Al Tabaa¹, manon Lesturgie¹, Pierre Régis Burgel², Nicolas Carlier² and Jérôme Avouac³, ¹Rheumatology Department, Cochin Hospital, Paris, France, ²Pulmonology department, Cochin Hospital, Paris, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Cystic fibrosis (CF) is the most common lethal autosomal recessive genetic disorder. The improvement in life expectancy due to the advent of new treatments…
Abstract Number: 0307 • ACR Convergence 2024
Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes
Sanat Phatak¹, Rucha Wagh², Smita Dhadge², Sarita Jadhav², Parth Ladha³, Rishi Nalkande⁴, Rohan Shah², Jennifer Ingram⁵ and Chittaranjan Yajnik², ¹KEM Hospital Research Centre, Pune, Maharashtra, India, ²KEM Hospital Research Centre, Pune, India, ³Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India, ⁴BJ Government Medical College, Pune, India, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Hand manifestations (limited joint mobility, [LJM]; flexor tenosynovitis, [FT]; carpal tunnel syndrome, [CTS]; Dupuytren disease, [DD]) are common complications in diabetes. Despite their heterogeneity…
Abstract Number: 0300 • ACR Convergence 2024
Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Raymond Lay¹, Sara Achenbach², Cynthia Crowson¹, Umar Ghaffar¹, Michelle Burke¹, Haraldur Bjarnason¹, Newton Neidert¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Idiopathic retroperitoneal fibrosis (RPF) / chronic periaortitis (CP) is an uncommon condition characterized by a fibroinflammatory periarterial soft tissue thickening around the infra-renal abdominal…
Abstract Number: 0215 • ACR Convergence 2024
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
Alexa Figueroa Baiges¹, David Gazeley², Monica Messina¹, Bret Hanlon³, Edmond Ramly⁴, Ann Rosenthal⁵, Laura Stewart⁶, Makeba Williams⁷, Heidi W. Brown⁸ and Christie Bartels⁹, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Indiana University School of Public Health, Bloomington, IN, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert and Medical College of Wisconsin, Milwaukee, WI, ⁷Washington University in St. Louis School of Medicine, St. Louis, MO, ⁸Division of Health Services Research & Implementation Science, Kaiser Permanente, San Diego, CA, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension accounts for >54% of modifiable cardiovascular disease (CVD) risk and although 49% of US outpatient visits occur in specialty clinics, only 10% of…
Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ummugulsum Gazel¹, Ozun Bayindir Tsechelidis³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth¹ and Sibel Aydin⁶, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…
Abstract Number: 0236 • ACR Convergence 2024
Impact of Socioeconomic Status on Infection-Related Hospitalization Risk in Patients with Systemic Autoimmune Diseases
Ana Cecilia Bardan-Inchaustegui¹, Angel Kevin Garza-Elizondo², Pablo Gamez-Siller³, Jorge Esquivel-Valerio⁴, Jesus Cardenas-de la Garza¹, Diana Elsa Flores-Alvarado⁵, Daniela Alejandra Salcedo-Soto⁶, Karla Judith Duran-Villarreal⁷, Alejandra Jacquelin Osuna-Corrales⁷, Elsa Catalina Davila-Correa⁷, Valeria Cantu-Martinez⁷, Debanhi Morales-Espronceda⁷, Derek de Jesus Gauna-Leal⁷, Andrea Axelle Prado-Prado⁷, Nathalia Valdez-Benavides⁷, Nirvana Amairany González-Ontiveros⁷ and Dionicio Galarza-Delgado⁸, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁷Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁸UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Socioeconomic status (SES) is associated with diseases and poor health outcomes, including delays in diagnosis and increased disease severity. Hospitalization, often due to infections,…
Abstract Number: 0329 • ACR Convergence 2024
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Raisa Silva¹, Manuel Carpio Tumba², Sneha Gupta³, Latika Gupta⁴, Pedro M Machado⁵, Julie Paik⁶, Diana Louden⁷, Lesley Ann Saketkoo⁸, Sebastian E. Sattui² and Didem Saygin⁹, ¹Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, ⁴Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, ⁵Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Washington Libraries, Seattle, WA, ⁸New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ⁹Rush University Medical Center, Chicago, IL
Background/Purpose: The growing number of randomized clinical trials (RCTs) in idiopathic inflammatory myopathies (IIMs) points to a promising future for therapeutics in IIM. Adequate representation…
Abstract Number: 0332 • ACR Convergence 2024
Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Sangmee Bae¹, Daniela Macrovic², Auguestine Chung², Jessica Channick², Andrea Oh¹, Jennifer Wang¹, Ani Shahbazian², Tiffany De Leon², Yuna Lee², Grace Kim², Donald Tashkin², Jonathan Goldin² and christina Charles-Schoeman³, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…
Abstract Number: 0336 • ACR Convergence 2024
Mortality: Comparison, Causes and Determinants in Subgroups of Idiopathic Inflammatory Myopathies
Aurore Larrauffie¹, Chloé Bost¹, Marie Faruch¹, Elisabeth Uro-coste¹, Grégoire Prevot¹, Thomas Villeneuve¹, Jérémy Zordan¹, Claire Barrier¹, Morgane Mourguet², Marie Guille¹, Laurent Sailler¹, Laurent Alric¹, Sébastien De Almeida Chaves¹ and Grégory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, ³Toulouse Rangueil University Hospital, Toulouse, France
Background/Purpose: Idiopathic Inflammatory Myopathies (IIMs) are a group of heterogeneous connective tissue diseases including dermatomyositis (DM), polymyositis (PM), anti-synthetase syndromes (ASS), immune-mediated necrotizing myopathies (NM),…
Abstract Number: 0339 • ACR Convergence 2024
Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study
Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
Abstract Number: 0289 • ACR Convergence 2024
Effectiveness of Rituximab in IgG4 Related Disease
Fernando Lopez-Gutierrez¹, Javier Loricera², Cristina Hormigos³, Dalifer Freites Nuñez⁴, Maria Rodriguez-Laguna⁵, Patricia Moya Albarado⁶, Marta López I Gómez⁷, Hèctor Corominas⁸, Maite Silva-Díaz⁹, GUILLERMO GONZALEZ ARRIBAS⁹, Angel Garcia-Aparicio¹⁰, Judit Font Urgelles¹¹, Ivette Casafont-Sole¹¹, Pablo Martínez Calabuig¹², Elisabet Castaneda¹³, Carolina Merino¹⁴, Raquel Zas¹⁵, Juan Molina-Collada¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Eva Galindez-Agirregoikoa¹⁸, Andrea Hernández-Martín¹⁹, Lucia Pantoja²⁰, Ignacio Brana Abascal²¹, Vega Jovani²², Elia Valls-Pascual²³, Natalia Mena Vázquez²⁴, Adela Gallego- Flores²⁵, Noelia Cabaleiro Raña²⁶, Raul Veroz²⁷, Mariano Andres²⁸, Santos Castañeda²⁹ and Ricardo Blanco-Alonso³⁰, and Rituximab in IgG4 Related Disease Spanish Cooperative Group, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁵Resident in Rheumatology, Madrid, Spain, ⁶Hospital de San Pau, Barcelona, Spain, ⁷Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ¹³Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ¹⁶Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁹Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ²⁰Complejo Hospitalario Segovia, Segovia, Castilla y Leon, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²²National Health system, Alicante, Spain, ²³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁴IBIMA, Málaga, Andalucia, Spain, ²⁵Hospital Perpetuo Socorro, Badajoz, Spain, ²⁶Hospital Universitario Montecelo, Pontevedra, Galicia, Spain, ²⁷Hospital de Merida, Merida, Extremadura, Spain, ²⁸Hospital General Universitario de Alicante, Alicante, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disease often associated with elevated serum IgG4 levels. High dose corticosteroids are the cornerstone of treatment, but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].